Various types of ICMs are involved in malignant diseases [30,31], including PD-1 and PD-L1, which are representative ICMs that are highly expressed in the tumor microenvironment, and ICIs targeting these molecules are utilized in immunotherapy. The gene discussed is RPL17; the disease is neoplasm.